This talk explores how model-informed drug development (MIDD) can evolve from a supportive tool into a central pillar of clinical strategy. Using the development of AZD8233—a novel PCSK9 antisense oligonucleotide—as a case study, the presentation will walk through how modeling guided key decisions from Phase 2b to Phase 3, including trial design, dose optimization, and cardiovascular risk prediction.